Roche
9115 Hague Road
Indianapolis
Indiana
46256
United States
Tel: 317-521-2000
Fax: 317-521-2090
Website: http://www.roche.com/
About Roche
Founded in 1896, Roche is a global pioneer in pharmaceuticals and diagnostics and is the world’s largest biotech company, focused on advancing science to improve people’s lives. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics. The Diagnostics division develops and produces medical tests that provide information to help healthcare professionals find the right treatment for patients and deliver the best patient care to improve, prolong and save lives.
We offer a wide range of research and in vitro (outside the body) diagnostic tools that help in the early detection, prevention, diagnosis and treatment of diseases like congestive heart failure, HIV, hepatitis and diabetes, as well as medical conditions like fertility and blood coagulation. These products and services are used by researchers, physicians, patients, healthcare facilities and laboratories around the world.
Roche Diagnostics has its North American headquarters in Indianapolis. The Roche campus, located at 96th Street and Hague Road, spans about 155 acres and is home to U.S. research and development, laboratory, manufacturing, distribution, IT and administrative operations. The campus supports six diagnostics business areas: Diabetes Care, Centralized Diagnostics, Sequencing and Life Science, Molecular Diagnostics, Point of Care Diagnostics and Tissue Diagnostics. About 4,000 employees report into Indianapolis, with about 2,900 working onsite.
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
California Location:
4300 Hacienda Drive
Pleasanton, California 94588
United States
Tel: 925-730-8000
Fax: 925-225-0479
1950 articles with Roche
-
Carrick Therapeutics Announces Collaboration with Roche to Evaluate Novel Samuraciclib Combination to Treat HR+ Breast Cancer
8/2/2021
Carrick Therapeutics today announced a clinical collaboration with Roche to evaluate a novel combination of Carrick’s samuraciclib and Roche’s giredestrant in CDK4/6i resistant HR+, HER2- metastatic breast cancer.
-
Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.
-
The antibody is still being evaluated in clinical studies, with a large-scale Phase III trial expected to wrap in the second half of 2022.
-
The company’s technology is designed to attach any off-the-shelf antibody with any payload without the need for modification.
-
Genentech’s Hemlibra showed no new safety signals and continued to deliver consistent bleeding control in the final analysis of a long-term, late-stage hemophilia A study.
-
In its 2Q2021 Clinical Report, BioSpace highlights drugs that were greenlit for clinical studies, faced clinical and regulatory hurdles and some who saw regulatory wins.
-
The WHO is calling for manufacturers to cut prices and increase the availability of supplies to low- and middle-income nations to parts of the world where COVID-19 continues to surge.
-
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
-
Female-Founded Antheia Raises $73 Million to Support Synthetic Biology for Essential Medicines
6/30/2021
Christina Smolke said the financing will enable the company to use its synthetic biology platform to support essential medications that rely on plant-based materials. -
The deal was originally inked in 2005, where U.S.-based Chiron Corp. made payments to Genentech, a Roche company.
-
Roche had a big week, scoring wins but also stepping away from its gene therapy partnership with 4D Molecular Therapeutics.
-
Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target
6/24/2021
Vividion Therapeutics, Inc. today announced that it has earned its first milestone payment related to its exclusive worldwide collaboration, option and license agreement with Roche.
-
The company said it will file a marketing application later this year for the drug under the FDA’s accelerated approval pathway.
-
Roche presented results from several Phase II and III trials at the 7th Congress of the European Academy of Neurology (EAN) Annual Meeting held virtually June 19-22.
-
Roche SARS-CoV-2 molecular test granted first FDA Emergency Use Authorization for PCR testing of both symptomatic and asymptomatic individuals at the point of care
6/18/2021
Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the cobas® SARS-CoV-2 Nucleic acid test.
-
Three other drug contenders that work similarly to Biogen’s drug are currently in clinical trials and expecting data relatively soon.
-
Synlogic Enters Research Collaboration with Roche for Development of Novel Therapy to Treat Inflammatory Bowel Disease
6/17/2021
Synlogic, Inc. announced today that it has entered into a research collaboration agreement with Roche for the discovery of a novel Synthetic Biotic™ medicine for the treatment of inflammatory bowel disease (IBD).
-
Atea Pharmaceuticals Announces Achievement of AT-527 Development Milestone Under License Agreement with RocheMilestone in the amount of $50 million realized
6/16/2021
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of oral therapeutics for severe viral infections, announced that it has achieved a milestone associated with the development of AT-527 and expects to receive a related payment under its license agreement with Roche of $50 million.
-
The company says it plans to file an IND for the candidate, dubbed CFT8919, by the middle of next year.
-
The clinical trial, which will be conducted by Xilio, will assess XTX101's safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.